Epidermal growth factor receptor: An important target in esophageal cancer

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 10, 2013, Pages 1179-1185

  Hong, Liu ^a   Han, Yu ^a   Brain, Lubi ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidermal growth factor receptor; Esophageal cancer; Prognosis; Therapy

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN A5; CETUXIMAB; CH 806; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; MATUZUMAB; NIMOTUZUMAB; PANITUMUMAB; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; ZALUTUMUMAB;

APOPTOSIS; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOREACTIVITY; NONHUMAN; PROTEIN TARGETING; REVIEW; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84884565096     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.820709     Document Type: Review

References (60)

1. Hong L, Li S, Han Y, et al. Angiogenesis-related molecular targets in esophageal cancer. Expert Opin Investig Drugs 2011;20:637-44
2. Ohtsu A. Chemoradiotherapy for esophageal cancer: current status and perspectives. Int J Clin Oncol 2004;9:444-50
3. Shitara K, Muro K. Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. Gastrointest Cancer Res 2009;3:66-72
4. Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancers. Cancer Invest 2003;21:887-96
5. McNamara MJ, Adelstein DJ. Current developments in the management of locally advanced esophageal cancer. Curr Oncol Rep 2012;14:342-9
6. Homs MY, Voest EE, Siersema PD. Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs 2009;14:329-39
7. Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007;298:70-82
8. Liu X, Wu WK, Yu L, et al. Epidermal growth factor-induced esophageal cancer cell proliferation requires transactivation of beta-adrenoceptors. J Pharmacol Exp Ther 2008;326:69-75
9. Boone J, van Hillegersberg R, Offerhaus GJ, et al. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus 2009;22:496-504
10. Sui G, Bonde P, Dhara S, et al. Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model. J Surg Res 2006;134:1-9
11. Hou Z, Sang S, You H, et al. Mechanism of action of (-)-epigallocatechin- 3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res 2005;65:8049-56
12. Pande AU, Iyer RV, Rani A, et al. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology 2007;73:281-9
13. Aiello M, Vella N, Cannavo C, et al. Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). Mol Med Rep 2011;4:203-8
14. Yarom N, Jonker DJ. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med 2011;11:95-105
15. Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13
16. Weickhardt AJ, Tebbutt NC, Mariadason JM. Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. Curr Cancer Drug Targets 2010;10:824-33
17. Ponz-Sarvise M, Rodr?guez J, Viudez A, et al. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J Gastroenterol 2007;13:5877-87
18. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009;20:851-5
19. de Castro-Carpeno J, Belda-Iniesta C, Casado Saenz E, et al. EGFR and colon cancer: a clinical view. Clin Transl Oncol 2008;10:6-13
20. Tabernero J, Macarulla T, Ramos FJ, Baselga J. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005;16:1740-8
21. Faloppi L, Andrikou K, Cascinu S. Cetuximab: still an option in the treatment of pancreatic cancer? Expert Opin Biol Ther 2013;13:791-801
22. Maya S, Kumar LG, Sarmento B, et al. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. Carbohydr Polym 2013;93:661-9
23. Sundvall M, Karrila A, Nordberg J, et al. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Expert Opin Emerg Drugs 2010;15:185-201
24. Jiang Z, Li C, Li F, Wang X. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. PLoS ONE 2013;8:e56205
25. Bode U, Massimino M, Bach F, et al. Nimotuzumab treatment of malignant gliomas. Expert Opin Biol Ther 2012;12:1649-59
26. Erdem L, Giovannetti E, Leon LG, et al. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem 2012;12:1649-59
27. Yeung K, Carlson JJ. Clinical and economic review of erlotinib in non-small-cell lung cancer. Expert Rev Pharmacoecon Outcomes Res 2012;12:411-23
28. Seike M, Gemma A. Therapeutic biomarkers of EGFR-TKI. Gan Kagaku Ryoho 2012;39:1613-17
29. Norguet E, Dahan L, Seitz JF. Targeting esophageal and gastric cancers with monoclonal antibodies. Curr Top Med Chem 2012;12:1678-82
30. Troiani T, Martinelli E, Capasso A, et al. Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets 2012;13:802-10
31. al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993;54:213-19
32. Parthasarathy S, Dhayaparan D, Jayanthi V, et al. Aberrant expression of epidermal growth factor receptor and its interaction with protein kinase C delta in inflammation associated neoplastic transformation of human esophageal epithelium in high risk populations. J Gastroenterol Hepatol 2011;26:382-90
33. Upadhyay R, Jain M, Kumar S, et al. Interaction of EGFR 497ArgLys with EGF +61AG polymorphism: modulation of risk in esophageal cancer. Oncol Res 2008;17:167-74
34. Inada S, Koto T, Futami K, et al. Evaluation of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (p53, E-cadherin, epidermal growth factor receptor). Surg Today 1999;29:493-503
35. Dittadi R, Ruol A, Gion M, et al. Epidermal growth-factor receptors and erbb2 protein expression in esophageal cancer and normal mucosa. Oncol Rep 1995;2:381-5
36. Mukaida H, Toi M, Hirai T, et al. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 1991;68:142-8
37. Vashist YK, Trump F, Gebauer F, et al. EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer. Target Oncol 2013; Epub ahead of print
38. Lee JM, Yang SY, Yang PW, et al. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Ann Surg Oncol 2011;18 2066-73
39. Hoshino M, Fukui H, Ono Y, et al. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology 2007;74:15-21
40. Ichiba M, Miyazaki Y, Kitamura S, et al. Epidermal growth factor inhibits the growth of TE8 esophageal cancer cells through the activation of STAT1. J Gastroenterol 2002;37:497-503
41. Sutter AP, Hopfner M, Huether A, et al. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer 2006;118:1814-22
42. Guo XF, Zhu XF, Zhong GS, et al. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Oncol Rep 2012;27:1639-45
43. Gong JH, Liu XJ, Li Y, Zhen YS. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Cancer Chemother Pharmacol 2012;69:1323-32
44. Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 2010;17:1168-76
45. Guo M, Liu S, Herman JG, et al. Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol Ther 2006;5:152-5
46. Sudo T, Mimori K, Nagahara H, et al. Identification of EGFR mutations in esophageal cancer. Eur J Surg Oncol 2007;33:44-8
47. Grossmann AH, Samowitz WS. Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. Arch Pathol Lab Med 2011;135:1278-82
48. Ma ES, Ng WK, Wong CL. EGFR gene mutation study in cytology specimens. Acta Cytol 2012;56:661-8
49. Okano J, Gaslightwala I, Birnbaum MJ, et al. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 2000;275:30934-42
50. Takaoka M, Harada H, Andl CD, et al Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein Cancer Res 2004;64:7711-23
51. Morgan S, Grandis JR. ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res 2009;315:572-82
52. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8:492-503
53. Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2011;117:1409-14
54. Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. Cancer Biol Ther 2012;13:600-5
55. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-19
56. Javle M, Pande A, Iyer R, et al. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol 2008;31:329-34
57. Teraishi F, Kagawa S, Watanabe T, et al. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Lett 2005;579:4069-75
58. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667-73
59. Adelstein DJ, Rodriguez CP, Rybicki LA, et al. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs 2012;30:1684-9
60. Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13:5869-75